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Summary Nitrosoureas are the drugs most effective in the treatment of patients with intracerebral malignant
glioma. Their limiting toxicity is delayed myelosuppression. A prospective, randomised crossover study of
recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was performed in
patients receiving BCNU for relapsed glioblastoma, to investigate whether the resulting haematological
toxicity profile could be modified by rhGM-CSF. Adequate data for analysis were obtained in 13 patients.
Following BCNU, the nadir neutrophil count was higher in 12 out of 13 patients during the rhGM-CSF-
protected cycles compared with the unprotected cycles. The median nadir was also significantly higher (1.79,
CI 0.76-3.52, P<0.005). Five episodes of neutropenia (<2 x 109 1- ) occurred during the unprotected cycles
compared with none in the rhGM-CSF-protected cycles (P = 0.076). There was no evidence of any effect on
platelets. This result shows that the haematological toxicity profile following therapeutic doses of BCNU can
be modified. It suggests that rhGM-CSF and other growth factors should be investigated for clinical efficacy in
chemotherapy using nitrosoureas.
In addition to the difficulties that attend the chemotherapy of
solid tumours in other sites, the treatment ofmalignant brain
tumours (MBTs) is further complicated by access problems
owing to the presence of the blood-brain barrier (BBB). The
most successful agents in terms of response and palliation in
relapse as well as prolongation of survival in primary treat-
ment are the nitrosoureas, which readily gain access to the
central nervous system. However, their protracted haemato-
logical toxicity profile limits scheduling possibilities (Martin-
dale, 1992). In tumours such as malignant glioma which have
rapid proliferation kinetics (Hoshino et al., 1992), this is a
serious disadvantage. A means of increasing the schedule
frequency for these drugs could have important implications.
The availability of haemopoietic colony-stimulating factors
raises the possibility of modifying the haematological toxicity
profile for the nitrosoureas and hence of accelerating the
scheduling frequency.
In 1988 McElwain presented the rationale for the
intensification of the treatment of glioma with nitrosourea
(Mbidde et al., 1988). His study of high-dose BCNU with
bone marrow rescue produced modestly encouraging results
which were marred by non-haematological toxicity. While
this may always limit the use of these drugs in ultrahigh
dose, the rationale for limited dose escalation remains. It
therefore seems appropriate also to investigate colony-
stimulating factors for their potential to allow dose escala-
tion.
Recombinant human granulocyte-macrophage colony-
stimulating factor (rhGM-CSF) is a haematopoietic growth
factor which has been shown in vitro to affect the develop-
ment and function of progenitor granulocyte, eosinophil and
macrophage lineages. It facilitates myeloid progenitor cell
division and modulates the function of mature neutrophils
and macrophages to promote microbial killing. Comprehen-
sive reviews of the preclinical investigation of rhGM-CSF are
available (Dunlop et al., 1991; Lieschke et al., 1992a). There
have also been reports of a beneficial effect on platelet tox-
icity (Brandt et al., 1988; Steward et al., 1990). Since the first
combination of rhGM-CSF with a chemotherapy regimen
was reported by Antman et al. (1988), a number of phase II
studies have been reported using different regimens. These
have been reviewed by Lieschke et al. (1992b). To date no
phase II studies have been reported using rhGM-CSF with
nitrosoureas. We therefore conducted a prospective, con-
trolled, randomised crossover study to investigate the effect
of rhGM-CSF in the first two cycles of BCNU therapy given
to patients as treatment for relapsed malignant glioma.
Patients and methods
Patient characteristics
Patients were eligible if they had biopsy-proven malignant
intracranial glioma suitable for treatment with chemotherapy.
The tumour could be newly diagnosed or recurrent after
surgery and radiotherapy but had to be measurable on con-
temporary CT scan. Patients may not have received prior
chemotherapy. All patients had normal renal function and
hepatic enzyme levels less than or equal to twice the upper
limit of normal.
All but two patients were receiving dexamethasone in
doses ranging from 1 to 16 mg daily. The dose was altered
during the study according to clinical need. Other drugs
commonly taken included anticonvulsants, analgesics, ben-
zodiazepines and H2-receptor blockers.
Therapeutic regimen
All patients were treated with intravenous BCNU (Carmus-
tine) 200 mg m-2 every 6 weeks. Oral chlorpromazine
25-50 mg was used as an antiemetic. The study period com-
prised of the first 12 weeks only; a final assessment was,
however, made at week 14.
Patients were randomised to receive rhGM-CSF with
either the first or second cycle of chemotherapy. Treatment
with rhGM-CSF (3 fig kg-' day-1) as subcutaneous injec-
tions began 24 h after BCNU. The protocol required that
treatment should continue until a white cell nadir was recog-
nised and the count had risen again to 3 x I0 - 1, when it
would be stopped indefinitely. If no recognisable nadir occur-
red dosing would be continued until the day preceding the
next dose of chemotherapy. Frequently with patients on
rhGM-CSF no clearly recognisable nadir was seen and the
growth factor was stopped early for a variety of reasons.
If at any time the white cell count exceeded 20 x I0'1-
dosing was suspended until it returned to below 10 x I10 1'.
If this happened on two occasions dosing was stopped
altogether. Provision was made for stopping the trial early
for any patient who demonstrated excess toxicity (WHO
grade 3 or 4) relating to the treatment regimen or whose
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disease was found to be progressing. Patients were considered
evaluable if they received more than 7 days of rhGM-CSF.
Investigations
Pretreatment investigations included a haematological profile,
tests of hepatic and renal function including creatinine
clearance, ECG and chest radiograph. A full neurological
examination was performed.
A full blood count and differential was performed twice
weekly. The patient was assessed for toxicity and disease
response each week, when a full biochemical profile was also
obtained. A CT scan was performed at completion of the
study to assess response. Patients with stable disease or who
were showing response could proceed to further cycles of
chemotherapy, but these were not accompanied by rhGM-
CSF.
The study was approved by the Western Research Ethics
Committee and informed consent was obtained in all cases.
Statistical methods
The study was designed to have a 90% chance of detecting a
1 week shift in the occurrence of the white cell count nadir at
the 5% level of statistical significance. On this basis it was
calculated that data on ten evaluable patients would be
required. However, because of the possibility of patients
becoming unevaluable extra recruitment to compensate for
this was made and information on 13 evaluable patients was
actually obtained.
Patients were allocated to receive rhGM-CSF on either
cycle 1 or cycle 2 at random, using random permuted blocks
of size 4.
After the study was completed a cursory examination of
the blood profiles revealed that the timing of the white count
nadir was not at all distinct for the majority of patients. This
end point was therefore not amenable to statistical analysis.
The analysis presented here concentrates on the secondary
end points - 'nadirs' and 'values in week 6' for neutrophils,
white count and platelets.
The only blood counts considered for the main statistical
analysis were those in which there was a corresponding count
taken within 2 days (in terms of time from when BCNU was
given) in the other cycle. The 'nadirs' used are the minimum
of such values found on each cycle. The 'values in week 6'
consist of the latest recorded count on either cycle (between
day 36 and 42 of the cycle) and a corresponding count on the
other cycle taken within 2 days of it.
The analysis of all counts uses the non-parametric tech-
nique described by Jones & Kenward (1989, pp. 51-59). For
the analysis of the incidence of very low counts (for neut-
rophils and white cells) the adjusted version of Prescott's test
was used (Jones & Kenward, 1989, pp. 98-100). In none of
the analyses was there any evidence of treatment carry-over
even at the 20% level of significance.
Results
Patients
A total of 19 patients with malignant glioma were ran-
domised into the study. Seventeen had intracranial tumours
recurrent after surgery and radiotherapy. Two patients had
undergone biopsy only and had received no further therapy
other than corticosteroids at the time of randomisation. Six
patients were excluded from the efficacy analysis, four
because of disease progression, one who received no rhGM-
CSF because of BCNU toxicity in the first cycle and one
patient who received only 6 days of growth factor. Two
patients in whom rhGM-CSF was stopped early because of
toxicity had by then received 19 and 24 days of drug and are
included in the efficacy analysis. All patients were included in
the analysis of toxicity.
Thirteen patients were included in the efficacy analysis.
Their details are shown in Table I. All completed two cycles
of BCNU without dose modifications of any kind. There
were no delays in treatment because of neutropenia following
cycles with or without rhGM-CSF. The median number of
days for which patients included in the efficacy analysis
received rhGM-CSF was 26 days (range 19-39).
Haematological effects
A typical profile of a blood count during treatment is seen in
Figure 1. rhGM-CSF was given for 23 days. Neutrophil
nadirs in both cycles occurred at a similar time but were not
as severe in the cycle with rhGM-CSF.
The median blood counts for each treatment group and
each cycle are presented in Table II. In Table III the
estimated effects of rhGM-CSF and cycle on the median
counts are given.
For neutrophil nadirs there was no discernible cycle effect,
but the effect of rhGM-CSF in ameliorating the nadir neut-
rophil count was highly significant (P=0.005). The nadir
count was higher for 12 of the 13 patients in the rhGM-CSF
cycle than in the cycle without rhGM-CSF.
Tables II and III show similar figures for the total white
cell count. There is again a significant rhGM-CSF effect in
raising the nadir, but this time there is a significant cycle
effect also. This implies a cumulative effect of the BCNU on
the non-neutrophil leucocyte component.
Table III shows differences in median neutrophil values in
week 6 for cycles with and without rhGM-CSF. Again there
is a significant influence of rhGM-CSF, which produces
higher levels of neutrophils (P = 0.003), while there is no
significant cycle effect (P = 0.72).
Altogether there were five neutrophil nadirs lower than
2 x 1091'. All occurred during courses unprotected by
rhGM-CSF. This reduction in the incidence of neutrophil
nadirs less than 2 did not quite reach conventional levels of
statistical significance (P = 0.076) but, nevertheless, taken
with the other evidence, is indicative of a protective effect of
rhGM-CSF.
An examination ofplots such as Figure 1 revealed that for
many patients the exact timing of the neutrophil nadir was
indistinct. However, given these difficulties, it still did not
appear that the effect of rhGM-CSF was to alter the timing
of the neutrophil nadir.
Table III also shows differences in the median of the
platelet nadirs. rhGM-CSF had no effect on these (P = 0.62),
although there was a strong cycle effect (P = 0.038), showing
Table I Pretreatment characteristics (of the 13 patients to be used
in the efficacy analysis)
Frequency (
Age
Median 46
Interquartile range 41-55
Range 27-62
Cycle on which GM-CSF given
1 7 54
2 6 46
ECOG performance status
0 1 8
1 10 77
2 2 15
Sex
Male 4 31
Female 9 69
Type of disease
New 2 15
Recurrent 11 85
Neurology
No deficit 10 77
Some deficit 3 23EFFECT OF rhGM-CSF ON BCNU 543
the cumulative toxic effect of the nitrosoureas on this com-
partment of the myeloproliferative system. This is also
emphasised in the 6 week levels, which are included in the
table.
Toxicity
All 19 patients (34 cycles of BCNU, 16 courses of rhGM-
CSF) were available for assessment ofinfectious episodes and
toxicity. Seven episodes of infection were recorded, five in
rhGM-CSF cycles and two in cycles without rhGM-CSF.
Five were bacterial, one viral and one undetermined. Four
infections were of the upper respiratory tract, one the lower
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respiratory tract, one the conjunctiva and one the gas-
trointestinal tract. None was considered serious and no
patient required hospitalisation.
The principal toxicity attributed to rhGM-CSF was
cutaneous. A majority of patients (10/19) developed some
form of skin reaction. In most this comprised raised,
erythematous, pruritic wheals at the injection site. These
reactions were generally mild and did not necessitate inter-
ruption of treatment. In one case the skin reaction was severe
and was accompanied by bone pain so that treatment was
terminated. Another patient suffered severe skin wheals and
epigastric discomfort 1 h after rhGM-CSF that could be
relieved by prophylactic paracetamol. All other side-effects
[bone pain (3), headache (4) and nausea (3)] were infrequent
and mild at this dose level (Table IV).
The only symptomatic side-effects reported with the
BCNU were nausea and vomiting.
Response
At a 14 week assessment 26% of the patients (5/19) showed
clinical and radiological evidence of response. This response
rate is that which would be expected for nitrosourea alone in
this group of patients (Table V).
Discussion
The nitrosoureas are a group of cytotoxic drugs which are
useful in a variety of conditions including lymphoma, gastro-
intestinal malignancy and gliomas. Their activity derives
0
Table III Estimated effects of GM-CSF
blood counts
and treatment cycle on
Figure 1 Neutrophil profiles (10' I) for a patient receiving two
consecutive cycles (--, cycle 1: -, cycle 2) of BCNU with (0) and
without (l) rhGM-CSF (tg kg-'). 'G' indicates days on which
patients received rhGM-CSF.
Table n Median blood counts (interquartile ranges in italics)
Treatment
Cycle group Cycle 1
2
White count nadir
GM-CSF given 8.1 3.9
on cycle 1 (4.4-9.3) (2.4-7.5)
GM-CSF given 3.8 5.7
on cycle 2 (1.6-4.4) (4.4-7.4)
White count in week 6
GM-CSF given 9.0 4.8
on cycle 1 (5.0-9.9) (1.6-6.9)
GM-CSF given 6.1 12.9
on cycle 2 (4.0-10.5) (4.7-13.7)
Neutrophil nadir
GM-CSF given 4.79 2.30
on cycle 1 (2.86-4.99) (0.75-3.04)
GM-CSF given 2.21 4.03
on cycle 2 (1.20-4.58) (3.15-5.99)
Neutrophil count in week 6
GM-CSF given 4.79 2.80
on cycle 1 (3.90-7.02) (1.04-3.39)
GM-CSF given 3.39 8.37
on cycle 2 (1.93-8.13) (3.90-10.98)
Platelet nadir
GM-CSF given 104 49
on cycle 1 (68-116) (38-131)
GM-CSF given 138 89
on cycle 2 (80-167) (38-177)
Platelet count in week 6
GM-CSF given 344 164
on cycle 1 (191-388) (65-408)
GM-CSF given 348 184
on cycle 2 (268-375) (150-217)
Approximate
Estimated 95% CI for
difference in difference in
medians medians P-value
White count nadir
Treatment cyclea 1.2 0.3-2.3 0.027
GM-CSFb 2.4 1.2-3.9 0.003
White count in week 6
Treatment cycle 0.2 - 2.7-2.0 0.943
GM-CSF 2.9 0.3-6.3 0.038
Neutrophil nadir
Treatment cycle 0.47 - 1.05-1.68 0.353
GM-CSF 1.79 0.76-3.52 0.005
Neutrophil count in week 6
Treatment cycle -0.15 - 1.81-1.46 0.721
GM-CSF 2.48 1.46-5.43 0.003
Platelet nadir
Treatment cycle 40 1-69 0.038
GM-CSF - 4 - 32-36 0.617
Platelet count in week 6
Treatment cycle 89 14-201 0.027
GM-CSF - 55 - 138-43 0.284
aThe estimated difference in medians is for cycle 1 - cycle 2, i.e. a
positive value indicates progressive myelosuppression. the estimated
difference in medians is between the cycle with GM-CSF and the
cycle without, i.e. a positive difference indicates GM-CSF is having a
protective effect.
Table IV Toxicity attributable to rhGM-CSF
Number of Worst
patients (19) grade (WHO)
Cutaneous 7 1
3 2
Bone pain 2 1
1 2
Headache 2 1
2 2
Nausea 2 1
1 3
a
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Table V Week 14 clinical assessment (for all 19 patients)
Frequency %
Improved 5 26
Unchanged 6 32
Worsea 8 32
aThis includes one patient who progressed during cycle 1 but had
improved by week 14 (patient 3). It also includes one patient who
was too ill to keep the appointment for her clinical assessment
(patient 15).
from the formation of DNA cross-linkage and the depletion
of glutathione, but it appears from in vitro studies that they
do not share cross-resistance with classical alkylating agents.
Their principal toxic effect is on the bone marrow, which
leads to clinically relevant neutropenia and throm-
bocytopenia. While thrombocytopenia is more common,
neutropenia may be profound and dose-limiting (Martindale,
1992). Both phenomena occur later than with most com-
monly used cytotoxic agents. Nadirs typically occur at 4-6
weeks but may sometimes persist until week 7 or 8. This
feature limits the usefulness of this class of drug since the 6
week delay which is usually necessary between cycles allows
regrowth of tumours with rapid cell proliferation kinetics. If
a method could be devised for safely increasing the frequency
with which these drugs could be delivered their value in
treating malignant tumours could be considerably enhanced.
The nitrosoureas remain the most useful class of drug in
the treatment of malignant glioma. Their non-ionised highly
lipid-soluble nature allows them ready access to the brain.
BCNU is the most studied drug in this disease and is still
generally thought to be the most effective, although
modifications to the basic structure may produce some
advantages (Gregor et al., 1992). Response occurs in approx-
imately 30% ofpatients with recurrent disease, and there is a
modest prolongation of survival when used in the adjuvant
setting (Stenning et al., 1987). It is recognised that the
therapeutic index for BCNU is low (Kornblith et al., 1988),
being limited in the first instance by marrow toxicity.
Attempts have been made to improve this by using ultrahigh
dose BCNU with bone marrow rescue (Hochberg et al., 1981;
Mbidde et al., 1988). While a possible improvement in sur-
vival was observed, justifying the rationale of the approach,
non-haematological toxicity remained a problem. An alterna-
tive and potentially less toxic approach might be to employ a
more modest dose intensification scheme either by
accelerating the frequency of the drug or by dose escalation
under colony-stimulating factor cover.
Our results show that the neutrophil toxicity of BCNU, at
least in the first two cycles, is indeed reduced by rhGM-CSF.
The nadir neutrophil count was higher for 12 out of 13
patients in the protected cycle compared with the unpro-
tected cycle. The resulting median nadir was significantly
higher in the cycles with rhGM-CSF. There was no sugges-
tion of a cycle effect, which was not true for either platelets
or the total white count. Thus, if neutropenia were thought
to be the limiting toxicity it may be possible to increase the
administered dose safely and over a number of courses of
BCNU.
No alteration could be observed in the timing of the
neutrophil nadir, although it must be said that the nadirs in
the rhGM-CSF cycles were frequently indistinct or even non-
discernible. However, no episodes of grade 1 neutropenia
were seen during the protected courses compared with five
during courses not protected by rhGM-CSF. Hence, if neut-
rophil toxicity were normally dose limiting it still might be
possible to increase the drug cycle time using these same
doses. The therapeutic implications of this for malignant
glioma are considerable since it might allow two or more
cycles of drug to be given between surgery and radiotherapy
at a time when the proliferative potential of the tumour is
high. Radiotherapy remains the first-line treatment of this
condition but must be delayed several weeks following
surgery to allow wound healing and treatment planning. An
effective means of treatment at this stage could possibly
enhance the value of radiotherapy.
Although rhGM-CSF, when infused or given sub-
cutaneously, undoubtedly causes a rise in neutrophils and
eosinophils and less profoundly in monocytes and lym-
phocytes, its influence on platelets is less clear. Edmondson et
al. (1989) have shown that twice-daily subcutaneous GM-
CSF improves the platelet counts of patients being treated
with carboplatin and cyclophosphamide, and Steward et al.
(1990) have suggested benefit after treatment with high-dose
melphalan. However, we saw no improvement in platelet
count after treatment with BCNU and this toxicity would
preclude any nitrosourea dose escalation with this colony-
stimulating factor alone.
Toxicity seen with rhGM-CSF was similar to that reported
elsewhere (Steward et al., 1989) and predominantly involved
skin rashes. No cardiac toxicity was noted and bone pain and
headache at this dose were infrequent and mild.
No serious infections were seen in either group of patients,
and it seems that at this dose BCNU is a safe drug even
without rhGM-CSF protection. This would give further
encouragement to consider dose or frequency escalation.
We conclude therefore that the neutrophil toxicity profile
of BCNU can be favourably affected by rhGM-CSF. This
could allow dose intensity escalation, although platelet tox-
icity may then become a limiting factor. With this in mind a
similar study using interleukin 6 (IL-6) in combination with
BCNU is under way. Future studies of such combinations of
growth factors will need to include an assessment ofpotential
protection over a full treatment course because of the pos-
sibility of cumulative toxicity extending beyond the first two
cycles.
We are grateful to Schering Plough/Sandoz for their data manage-
ment support and for supply of rhGM-CSF. Data collection and
analysis was undertaken through the Beatson Oncology Centre
Clinical Trials Unit, which is supported by the Cancer Research
Campaign.
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